Paulino R

Language: Spanish
References: 26
Page: 145-148
PDF size: 190.48 Kb.

ABSTRACT

In HIV-1 infection, its CD4+ T lymphocyte tropism, the T-dependent B-lymphocyte activation is drastically delayed. A 10-30% of individuals infected with HIV are able to develop serological activity to generate neutralizing responses against some HIV subtypes. These individuals are better known as elite controllers. Neutralizing antibodies generated in this situation are characterized against V3 hypervariable loop of gp120, better known as 447-52D; these are not related to a higher neutralizing potency but to a higher specificity against protein structures found in the virus. Neutralizing antibodies are characterized by a higher rate of somatic mutations. Despite the success of immunotherapy in bacterial and viral infections, researchers are not yet able to demonstrate that the long-term use of antibodies against HIV-1 will control the infection; this is base on HIV-1 rapid escape and molecular modifications.

REFERENCES

1. Abela, IA., y col. PloS Pathog. 2012; 8, e1002634.

2. Bonsignori, M., Pollara, J., y cols. “Antibody-dependent celular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family”. J Virol 2012; 86, 11521-11532.

3. Doria-Rose, N., Klein, R., Manion, M., y cols. “Frequency and phenotype of human immunodeficiency virus envelop- specific B cells from patients with broadly cross-neutralizing antibodies”. J. Virol. 2009; 83, 188-199.

4. Eichberg, JW., Murthy, K., Ward, RH., y cols. “Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG.” AIDS Res. Hum. Retroviruses 1992; 8, 1515.

5. Forthal, DN.,Moog, C. “Fc receptor-mediated antiviral antibodies”. Curr. Opin. HIV AIDS 2009; 4, 388-393.

6. Frederick, R., Nagel, J., Fireman, P. “Antitoxin responses in the elderly to tetanus-diphtheria (TD) Immunization”. Am. J. Epidemiolo 1978; 108(2): 145-149.

7. Good-jacobson, KL., Shlomchik, MJ. “Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics”. J Immunol 2010; 185, 3117-3125.

8. Gorny, M., Xu, JY., Karwowska, S., Buchbinder, A., y cols. “Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp-120”. J. Immunol 1993;150, 635-643.

9. Gray, ES., Madiga, MC., Hermanus, T., y cols. “The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection”. J. Virolo 2011; 85,4828-4840.

10. Haynes, BF., Gilbert, PB., y cols. “Immune-correlates analysis of an HIV-1 vaccine efficacy trial”. N Engl J Med 2012; 366, 1275-1286.

11. Igarashi, T., Brown, C., Azadegan, A., y cols. “Human Immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma”. Nat. Med. 1999; 5, 211-216.

12. Klein, F., Gaebler, C., y cols. “Broad Neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein”. J Exp Med 2012; 209, 1469-1479.

13. Liao HX., Lynch, R., Zhou, T., Gao, F., y cols. “Co-evolution of a broadly neutralizing HIV-1 antibody and immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies”. J. Virolo. 1999; 73, 4009-4018.

14. Mascola, JR., Stiegler, G., y cols. “Protection of macaques against vaginal transmission of a pathogenic immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies”. J. Virolo. 1999; 73, 4009-4018.

15. Mascola, JR., Stiegler, G., y cols. “Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusión of neutralizing antibodies”. Nat. Med. 2000; 6, 207-210.

16. McLellan, JS., Pancera, M., y cols. “Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9”. Nature 2011;480, 336-343.

17. Baba, TW., Liska, V., Hofmann-Lehmann, R., y cols. “Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection”. Nat. Med. 2000; 6, 200-206.

18. Mikell, I., Sather, DN., Kalams, S., y cols. “Characteristics of the earliest cross-neutralizing antibody response to HIV-1”. PloS Pathog 2011; 7, e1001251.

19. Poignard, P., Sabbe, R., y cols. “Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo”. Immunity 1999; 10, 431-438.

20. Rajewsky, K. “Clonal selection and learning in the antibody system”. Nature 1996;381, 751-758.

21. Rerks-Ngarm, S., Pitisuttithum, P., y cols. “Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand”. N. Engl. J M 2009; 361, 2209-2220.

22. Sather, DN., Armann, J., y cols. “Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection”. J. Virol 2009; 83, 757-769.

23. Scheid, JF., Mouquet, H., y cols. “Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding”. Science 2011; 333, 1633-1637.

24. Tiller, T., y cols. “Autoreactivity in human IgG+ memory B cells”. Immunity 2007; 26, 205-213.

25. Trkola, A., Kuster, H., Rusert, P., y cols. “Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies”. Nat Med 2005; 11, 615-622.

26. West, AP., Scharf, L., Horwitz, J., Klein, MC., y cols. “Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residue”. Proc Natl Acade Sci U.S.A. 2013; 110, 10598-10603.